{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:10:38Z","timestamp":1790892638817,"version":"4.1.0"},"reference-count":39,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["338374"],"award-info":[{"award-number":["338374"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","award":["220111"],"award-info":[{"award-number":["220111"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Juselius Foundation","doi-asserted-by":"publisher","award":["338374"],"award-info":[{"award-number":["338374"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Juselius Foundation","doi-asserted-by":"publisher","award":["220111"],"award-info":[{"award-number":["220111"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The fluorescence in situ hybridization (FISH) technique plays an important role in the risk stratification and clinical management of patients with chronic lymphocytic leukemia (CLL). For genome-wide analysis, FISH needs to be complemented with other cytogenetic methods, including karyotyping and\/or chromosomal microarrays. However, this is often not feasible in a diagnostic setup. Optical genome mapping (OGM) is a novel technique for high-resolution genome-wide detection of structural variants (SVs), and previous studies have indicated that OGM could serve as a generic cytogenetic tool for hematological malignancies. Herein, we report the results from our study evaluating the concordance of OGM and standard-of-care FISH in 18 CLL samples. The results were fully concordant between these two techniques in the blinded comparison. Using in silico dilution series, the lowest limit of detection with OGM was determined to range between 3 and 9% variant allele fractions. Genome-wide analysis by OGM revealed additional (&gt;1 Mb) aberrations in 78% of the samples, including both unbalanced and balanced SVs. Importantly, OGM also enabled the detection of clinically relevant complex karyotypes, undetectable by FISH, in three samples. Overall, this study demonstrates the potential of OGM as a first-tier cytogenetic test for CLL and as a powerful tool for genome-wide SV analysis.<\/jats:p>","DOI":"10.3390\/cancers15041294","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T01:36:37Z","timestamp":1676856997000},"page":"1294","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Optical Genome Mapping as an Alternative to FISH-Based Cytogenetic Assessment in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"15","author":[{"given":"Andriana","family":"Valkama","sequence":"first","affiliation":[{"name":"Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vorimo","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-8929","authenticated-orcid":false,"given":"Timo A.","family":"Kumpula","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannele","family":"R\u00e4s\u00e4nen","sequence":"additional","affiliation":[{"name":"Northern Finland Laboratory Centre Nordlab, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eeva-Riitta","family":"Savolainen","sequence":"additional","affiliation":[{"name":"Northern Finland Laboratory Centre Nordlab, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2449-0521","authenticated-orcid":false,"given":"Katri","family":"Pylk\u00e4s","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, 90220 Oulu, Finland"},{"name":"Northern Finland Laboratory Centre Nordlab, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-4403","authenticated-orcid":false,"given":"Tuomo","family":"Mantere","sequence":"additional","affiliation":[{"name":"Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit and Biocenter Oulu, University of Oulu, 90220 Oulu, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrc.2016.8","article-title":"The molecular pathogenesis of chronic lymphocytic leukaemia","volume":"16","author":"Fabbri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/asheducation-2009.1.421","article-title":"Predicting clinical outcome in CLL: How and why","volume":"2009","author":"Shanafelt","year":"2009","journal-title":"Hematology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clml.2017.11.010","article-title":"Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization\/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry","volume":"18","author":"Mato","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1038\/s41375-019-0378-z","article-title":"European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms","volume":"33","author":"Rack","year":"2019","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"34398","DOI":"10.18632\/oncotarget.26146","article-title":"Biological significance and prognostic\/predictive impact of complex karyotype in chronic lymphocytic leukemia","volume":"9","author":"Cavallari","year":"2018","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","article-title":"Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact","volume":"133","author":"Baliakas","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1097\/HS9.0000000000000707","article-title":"Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations","volume":"6","author":"Baliakas","year":"2022","journal-title":"Hemasphere"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"788761","DOI":"10.3389\/fonc.2021.788761","article-title":"Biology and Treatment of High-Risk CLL: Significance of Complex Karyotype","volume":"11","author":"Chatzikonstantinou","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Levy, B., Baughn, L.B., Akkari, Y.M.N., Chartrand, S., LaBarge, B., Claxton, D.F., Lennon, P.A., Cujar, C., Kolhe, R., and Kroeger, K. (2022). Optical Genome Mapping in Acute Myeloid Leukemia: A Multicenter Evaluation. Blood Adv., online ahead of print.","DOI":"10.1182\/bloodadvances.2022007583"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.ajhg.2021.06.001","article-title":"Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping","volume":"108","author":"Neveling","year":"2021","journal-title":"Am. J. Hum. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1038\/s41375-022-01652-8","article-title":"High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance","volume":"36","author":"Yang","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jmoldx.2022.09.009","article-title":"Clinical Validation and Diagnostic Utility of Optical Genome Mapping for Enhanced Cytogenomic Analysis of Hematological Neoplasms","volume":"24","author":"Sahajpal","year":"2022","journal-title":"J. Mol. Diagn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/ijc.33942","article-title":"Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML \/ MDS patients","volume":"150","author":"Gerding","year":"2022","journal-title":"Int. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/gcc.22971","article-title":"Optical genome mapping, a promising alternative to gold standard cytogenetic approaches in a series of acute lymphoblastic leukemias","volume":"60","author":"Lestringant","year":"2021","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00718-1","article-title":"Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS\/AML patients","volume":"12","author":"Balducci","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Puiggros, A., Ramos-Campoy, S., Kamaso, J., de la Rosa, M., Salido, M., Melero, C., Rodr\u00edguez-Rivera, M., Bougeon, S., Collado, R., and Gimeno, E. (2022). Optical Genome Mapping: A Promising New Tool to Assess Genomic Complexity in Chronic Lymphocytic Leukemia (CLL). Cancers, 14.","DOI":"10.3390\/cancers14143376"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ramos-Campoy, S., Puiggros, A., Kamaso, J., Be\u00e0, S., Bougeon, S., Larr\u00e1yoz, M.J., Costa, D., Parker, H., Rigolin, G.M., and Blanco, M.L. (2022). TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. Cancers, 14.","DOI":"10.3390\/cancers14153715"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1182\/blood-2009-10-201848","article-title":"Copy neutral loss of heterozygosity: A novel chromosomal lesion in myeloid malignancies","volume":"115","author":"McDevitt","year":"2010","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"80916","DOI":"10.18632\/oncotarget.13106","article-title":"Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations","volume":"7","author":"Blanco","year":"2016","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajh.23340","article-title":"Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia","volume":"88","author":"Fabris","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.leukres.2009.03.042","article-title":"Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages","volume":"34","author":"Chapiro","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428194.2013.845882","article-title":"Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia","volume":"55","author":"Houldsworth","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3109\/10428194.2012.723706","article-title":"MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia","volume":"54","author":"Cerri","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"key":"ref_27","first-page":"13","article-title":"Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia","volume":"1","author":"Chapiro","year":"2011","journal-title":"Am. J. blood Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.25385","article-title":"IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes","volume":"94","author":"Fang","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/10428194.2019.1675877","article-title":"The role of MYC in the transformation and aggressiveness of \u2018indolent\u2019 B-cell malignancies","volume":"61","author":"Filip","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54297","DOI":"10.18632\/oncotarget.17350","article-title":"Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53\/ATM FISH deletions","volume":"8","author":"Puiggros","year":"2017","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cancergen.2018.07.004","article-title":"Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia","volume":"228","author":"Chun","year":"2018","journal-title":"Cancer Genet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6778","DOI":"10.1158\/1078-0432.CCR-11-0785","article-title":"The Prognostic Significance of Various 13q14 Deletions in Chronic Lymphocytic Leukemia","volume":"17","author":"Ouillette","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4939-3302-0_7","article-title":"Fluorescent In Situ Hybridization in Suspension by Imaging Flow Cytometry","volume":"1389","author":"Maguire","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","article-title":"Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features","volume":"54","author":"Robbe","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41416-019-0502-x","article-title":"The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia","volume":"121","author":"Visentin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2006-07-034256","article-title":"Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays","volume":"109","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/ajh.26587","article-title":"Optical genome mapping for structural variation analysis in hematologic malignancies","volume":"97","author":"Smith","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1294\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:35:42Z","timestamp":1760121342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15041294"],"URL":"https:\/\/doi.org\/10.3390\/cancers15041294","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]}}}